Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT02885974
- Locations
- 🇺🇸
Baylor Clinic, Houston, Texas, United States
🇺🇸Harris Health System - Smith Clinic, Houston, Texas, United States
Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Hugh McMillan
- Target Recruit Count
- 1
- Registration Number
- NCT02876094
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT02850211
Celecoxib for Thyroid Eye Disease
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 7
- Registration Number
- NCT02845336
- Locations
- 🇺🇸
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
Pre-Prostatectomy Celecoxib or Placebo
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT02840162
- Locations
- 🇺🇸
Portland VA Medical Center, Portland, Oregon, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02839694
Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 210
- Registration Number
- NCT02827487
- Locations
- 🇪🇬
Cairo University Hospitals, Cairo, Egypt
Perioperative Use of a Selective COX2 Inhibitor in Patients Undergoing Elective Colorectal Surgery: the Effect on Post-operative Bowel Motility and Post-operative Pain
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT02790203
Evaluation of Perioperative Celecoxib for Hip Arthroscopy
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 98
- Registration Number
- NCT02779166
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 10
- Registration Number
- NCT02770378
- Locations
- 🇩🇪
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.